You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Harvesting specific plant metabolites from hairy root cultures using magnetized n

    SBC: NAPROGENIX, INC.            Topic: NCCIH

    DESCRIPTION: Plants produce a wide variety of valuable bioactive metabolites, but these are commonly present in low concentrations in the wild-type plant. This makes the separation and purification of these compounds complicated and expensive. The applicant company, Naprogenix Inc, has developed a technology for increasing the yields of specific bioactive metabolites in mutant plant cell cultures ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Mitochondrial Uncoupling as a Therapeutic Target in Obesity

    SBC: Nano-Mite Technologies, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Obesity is recognized as a national and global epidemic, as approximately 65% of adults in the United States are classified as overweight or obese as defined by body mass index (BMI). In fact, in the year 2000, the human race reached a historical landmark, when for the first time in history the number of adults with excess weight surpassed the number of those w ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Smartphone Help for DWI Offenders and Their Families: A B-SMART App

    SBC: KLEIN BUENDEL, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Driving while intoxicated (DWI) remains a substantial and preventable source of morbidity and mortality in the United States. A variety of sanctions and interventions have been attempted to reduce DWI in the U.S., including enhanced DWI enforcement efforts, stricter drunk driving laws, responsible alcohol beverage service training, and alcohol treatment. The Ig ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Testing Smad7-based biologics for treating chronic wounds

    SBC: Taiga Biotechnologies, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Chronic skin wounds associated with various diseases (e.g., diabetes) and aberrant healing from acute wounding (e.g., hypertrophic scarring) is a major health care burden, which need scientific discovery-based therapeutic interventions. Our previous studies show that Smad7, a TGFb signaling antagonist, accelerates skin wound healing. We have developed a Smad7 f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a new treatment for MS: Controlling CD40 in EAE

    SBC: Op-T-Mune, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): The National Multiple Sclerosis (MS) Society reports that 1.2 million people worldwide and more than 400,000 people in the U.S. have clinically diagnosed MS. Currently there are 10 FDA approved drugs for MS but none ofthe current drugs have impacted the course of MS to prevent relapses or progression of disease. An efficient means to control the autoimmune infl ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Minimal piggyBac vectors for chromatin integration

    SBC: EXSCIEN CORPORATION            Topic: NIGMS

    In this grant, we describe novel transposon piggyBac vectors engineered to deliver transgenes as efficiently as currently available piggyBac systems, but with significantly less helper DNA co-delivered into the host genome. To generate these plasmids, we first identified an important and previously unreported aspect of transposon biology, that the full-length terminal domains required for successf ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Enhancing mtDNA Repair During Stroke Reperfusion to Reduce Brain Damage

    SBC: EXSCIEN CORPORATION            Topic: NINDS

    DESCRIPTION (provided by applicant): Attempts to develop drug treatments for acute stroke have not fulfilled expectations. Perhaps best illustrating this unsatisfactory situation is the hisory of therapeutic strategies directed at the inhibition of reactive oxygen species (ROS). While decades of laboratory and clinical studies make it clear that ROS are pathogenically important across the entire s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. New Functionally-Graded Biohybrid Vascular Graft

    SBC: Vivo Biosciences Inc            Topic: NCATS

    DESCRIPTION (provided by applicant): In this Phase I STTR proposal, our RandD goal is the development and evaluation of a novel functionally-graded biohybrid vascular graft for small diameter (lt6 mm) coronary bypass applications. Tissue engineered vascular constructs developed to date have mostly utilized synthetic and animal- derived biomaterials and require pre-seeding of host cells before impl ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Transdermal Naltrexone for Opiate Addiction and Alcoholism

    SBC: ALLTRANZ, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and a large proportion of those need treatment for opiate pain reliever, heroin, and alcohol addiction. Naltrexone (NTX), an opioid antagonist, is currently used in oral tablet form to help maintain opio ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Exosomal drug formulations

    SBC: 3P BIOTECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): More people in the U.S. (160,340 per year) die of lung cancer than of prostate, breast, and colon cancer combined. The most common type of lung cancer, non-small-cell lung cancer (NSCLC), accounts for 75% of all lung cancers. Regrettably, 85% of all patients diagnosed with NSCLC eventually die of the disease within 5 years, due to micro-metastasis and relapse. ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government